LX2020 — Regulatory decision
2026
IND-enabling studies and regulatory engagement expected in 2026Source filing
LEXEO THERAPEUTICS INC · Data as of 2026-09-08
2026
IND-enabling studies and regulatory engagement expected in 2026Source filing
Q4 2026
12-month data available for all high-dose participants in Q4 2026Source filing
H2 2027
Topline data readout expected in second half of 2027Source filing
H1 2028
Potential BLA submission under accelerated approval pathway in first half of 2028Source filing